周四夜盘，吉利德科学（GILD）股价大涨8.08%，引发市场关注。这一显著涨幅主要源于公司重磅消息：其开发的突破性长效HIV预防药物来那帕韦（商品名：Yeztugo®）获得美国食品药品监督管理局（FDA）批准上市。
来那帕韦是美国首个且唯一一款每年仅需注射两次的长效HIV预防方案，标志着HIV预防领域迈出了重大一步。临床试验数据显示，来那帕韦在预防HIV感染方面表现出色，在PURPOSE 1和PURPOSE 2两项III期临床试验中，分别实现了100%和99.9%的HIV感染预防效果。这种创新性的长效注射剂有望显著提高患者的用药依从性，为HIV预防带来新的选择。
分析认为，来那帕韦的获批将进一步巩固吉利德科学在HIV治疗和预防领域的领先地位。公司已在全球多个国家和地区提交了监管审批申请，未来有望在更广泛的市场推广这一创新疗法。这一突破性进展不仅为患者带来新的治疗选择，也为吉利德科学开辟了新的增长空间，市场对公司未来在HIV领域的持续创新充满期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.